Cancer risk in severe alpha-1 antitrypsin deficiency: the importance of early identification
- PMID: 35595322
- DOI: 10.1183/13993003.00846-2022
Cancer risk in severe alpha-1 antitrypsin deficiency: the importance of early identification
Conflict of interest statement
Conflict of interest: A. Lindberg reports lecture honoraria from Boehringer Ingelheim and Novartis; personal fees for advisory board participation from AstraZeneca, GlaxoSmithKline, Novartis and Boehringer Ingelheim; outside the submitted work. All other authors have nothing to disclose.
Comment on
-
Cancer risk in severe alpha-1-antitrypsin deficiency.Eur Respir J. 2022 Oct 27;60(4):2103200. doi: 10.1183/13993003.03200-2021. Print 2022 Oct. Eur Respir J. 2022. PMID: 35361631
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical